A Study of BMS-986207 Given Alone and in Combination With Nivolumab or With Nivolumab and Ipilimumab in Advanced Solid Tumors

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

101

Participants

Timeline

Start Date

November 30, 2016

Primary Completion Date

January 25, 2024

Study Completion Date

January 25, 2024

Conditions
Broad Solid Tumor
Interventions
DRUG

BMS-986207

Specified dose on specified days

BIOLOGICAL

Nivolumab

Specified dose on specified days

BIOLOGICAL

Ipilimumab

Specified dose on specified days

Trial Locations (20)

6009

Local Institution - 0006, Nedlands

10032

Local Institution - 0003, New York

15213

Local Institution - 0009, Pittsburgh

19104

Local Institution - 0012, Philadelphia

19111

Local Institution - 0002, Philadelphia

84112

Local Institution - 0010, Salt Lake City

119074

Local Institution - 0020, Singapore

200542

Local Institution - 0018, Craiova

400015

Local Institution - 0016, Cluj-Napoca

407280

Local Institution - 0015, Florești

1040045

Local Institution - 0005, Chuo-ku

2778577

Local Institution - 0004, Kashiwa-shi

8420383

Local Institution - 0021, Santiago

07601

Local Institution - 0001, Hackensack

C1430EGF

Local Institution - 0023, CABA

X5002HWE

Local Institution - 0019, Córdoba

C1093AAS

Local Institution - 0022, Buenos Aires

K1H 8L6

Local Institution - 0008, Ottawa

M5G 2M9

Local Institution - 0007, Toronto

022328

Local Institution - 0017, Bucharest

Sponsors
All Listed Sponsors
collaborator

Ono Pharmaceutical Co. Ltd

INDUSTRY

lead

Bristol-Myers Squibb

INDUSTRY